The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive decision support tool (DST) in breast cancer: Automated National Comprehensive Cancer Network (NCCN) guidelines linked to living systematic literature review (SLR).
 
Peter Kaufman
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Honoraria - AstraZeneca; Eisai; Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech; Sanofi; Seagen; Sermonix Pharmaceuticals
Speakers' Bureau - Lilly
Research Funding - Eisai (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Lilly; Polyphor; Seagen
 
Anna Forsythe
No Relationships to Disclose
 
Rozee Liu
No Relationships to Disclose
 
Jessicca Rege
Employment - Sus Clinicals Inc.
 
Javier Cortes
Stock and Other Ownership Interests - Leuko (I); MAJ3 Capital
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung; Steamline Therapeutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Athenex; Bioasis; Biocon; Bioinvent; BioNTech SE; Boehringer Ingelheim; Bridgebio; Celgene; Cellestia Biotech; Circle Pharma; Clovis Oncology; Daiichi Sankyo; Delcath Systems; Ellipses Pharma; ERYTECH Pharma; Expres2ion Biotechnologies; GEMoaB; Gilead Sciences; GlaxoSmithKline; Hexagon Bio; HiberCell; Jazz Pharmaceuticals; Leuko; Lilly; Menarini; Merck Sharp & Dohme; Polyphor; Reveal Genomics; Roche; Seagen; SERVIER; Zymeworks
Research Funding - ARIAD (Inst); Astrazeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy.Aleix Prat, Antonio Llombart, Javier Cortés.US 2019/ 0338368 A1; Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A.
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Merck Sharp&Dhome; Novartis; Pfizer; Roche; Steamline Therapeutics